The Max Foundation Expands Agreement with Bristol-Myers Squibb
Since 2016, Bristol-Myers Squibb has formally partnered with The Max Foundation to assist cancer patients in under-resourced countries who are unable to access treatment. During that time, more than 327 patients in 21 countries have benefitted from our collaboration, and 256 are currently receiving ongoing treatment.
Under our updated agreement, Bristol-Myers Squibb has agreed to a forty-five percent increase in the maximum number of patients actively on treatment with their targeted cancer therapy, Sprycel®(dasatinib). In addition, Bristol-Myers Squibb will plan to make a monetary contribution to support system strengthening throughout the Max Access Solutions model, including initiatives increasing access to diagnostics, informational workshops, and one-to-one support.
Bristol-Myers Squibb has also extended its trusted partnership with The Max Foundation to provide technical assistance. Together, we’re enhancing the strong monitoring & evaluation framework already in place to help ensure access to treatment around the world.
All for Patients Like Carmen
Carmen is a retired bookkeeper and loving Filipino grandmother. She supports her family by tutoring her grandkids, sewing clothes, and cooking meals.
When she was first diagnosed with chronic myeloid leukemia (CML), Carmen began receiving free treatment through The Max Foundation. Her drug therapy worked well initially, but eventually she stopped responding and feared the worst: “My children did not know that I had already sewn my dress in preparation for my own funeral.”
Thanks to collaborations with pharmaceutical partners and the patient-centered approach of our Max Access Solutions, Carmen was able to switch to Bristol-Myers Squibb’s Sprycel®as a next-line option. Today, she’s still happily doting on her grandkids, and her family is happy too. Carmen is just one of hundreds being rescued for a second time, and one of more than 15,000 enrolled in our Max Access Solutions.
“As we work to expand oncology treatment access for patients in low-income countries, we are grateful to have steadfast partners like Bristol-Myers Squibb,” said Pat Garcia-Gonzalez, CEO and co-founder of The Max Foundation. “Their ongoing commitment to addressing the unmet needs of people living with cancer in neglected parts of the world demonstrates how the public and private sectors can come together with solutions that save lives right away. Together we are bringing hope to people that would have otherwise gone without treatment, and that brings hope for all the other patients we aim to reach in the near future.”
“At Bristol-Myers Squibb, we believe in The Max Foundation’s mission of increasing patient access to treatment, care, and support,” Amadou Diarra, Head, Global Policy, Advocacy & Government Affairs shared. “Their work supporting patients in low- and middle-income countries is strongly aligned with our company values around ensuring patients everywhere are able to benefit from our innovative products. We are proud of our partnership and how it has grown through the years and we are heartened by patient stories that show the true impact of our collaboration.”
We at The Max Foundation express our deepest thanks to Bristol-Myers Squibb for their continued partnership. Together, we are realizing a world where all people – people like Carmen – can face cancer with dignity and hope.
The Max Foundation is a global health organization that believes all people living with cancer have the right to access the best treatment and support. Through personalized access services, quality training and education, and global advocacy efforts, we aim to help people face cancer with dignity and hope.